ArticleActa pharmaceutica Sinica. B2026

A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy.

Chaoyan Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.